Total raised
$500K
Last: Pre-Seed 2020-07
Stage
Pre-Seed
Founded
2008
Headcount
1
HQ
Jerusalem
Sector
Health Tech & Life Sciences
About
TwoToBiotech's researchers have identified a novel human peptide hormone (P3) thatis expressed in activated immune cells. The company subsequently developed a platform technology with several specific monoclonal antibodies against P3 in order to treat autoimmune diseases. In-vivo studies show that the antibody may be effectivefor treatment of type 1 and type 2 diabetes. TwoToBiotech is developing another novel human peptide hormone, APC1, for treatment of type 2 diabetes. Initial tests on mice have shown promise. The company has also isolated a novel human cardiac peptide that may have the potential tostrongly regulate glucose metabolism.
Funding history · 1 round · $500K total
2020-07
Pre-Seed
$500K
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of TwoToBiotech's research and development?
- TwoToBiotech focuses on identifying novel human peptide hormones and developing platform technology with specific monoclonal antibodies to treat autoimmune diseases, specifically type 1 and type 2 diabetes.
- What is the status of TwoToBiotech as of March 2022?
- TwoToBiotech ceased to operate in March 2022 and is currently inactive.
- When was TwoToBiotech founded?
- TwoToBiotech was founded in January 2008.
- What was the total amount of funding raised by TwoToBiotech?
- TwoToBiotech raised a total of $500,000 in funding. For a full financing history, please refer to startupim.
- When did TwoToBiotech complete its last funding round and what type was it?
- TwoToBiotech completed its last funding round in July 2020, which was a Pre-Seed round.
- What is the current employee count for TwoToBiotech?
- TwoToBiotech has 1 employee.
- What specific peptide hormone is TwoToBiotech developing for type 2 diabetes treatment?
- TwoToBiotech is developing a novel human peptide hormone called APC1 for the treatment of type 2 diabetes, which has shown promise in initial tests on mice.
- Who are the founders of TwoToBiotech?
- The founders of TwoToBiotech are Orly Devary and Tamara Sandler.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
pharma-companiesmolecular-biologydiabetespharmaceuticalsautoimmune-diseases